Everything below concerns REV-ERB. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Signs and Symptoms Rough, red rash Lymphadenopathy Abnormal thickening of the palms of the hands and soles of the feet Hair loss of balding Nail trauma Ectropion Liver and Spleen become swollen 4 Stages (link) Diagnosis Physical exam to check for lesions Peripheral blood smear Use a microscope to count the number of blood cells and look at their shape. Skin biopsy Checks for signs of cancer Immunophenotyping Flow cytometry T-cell receptor gene rearrangement test Liver Function test HIV test X-ray, CT scan, and PET scan To determine if the lymphoma is metastatic Treatments Chemotherapy Radiation Drug Therapy Photodynamic Therapy Biologic Therapy using Interferon Targeted Therapy UV Radiation Therapy Clinical Trials being pursued Stem cell transplant combined with chemoradiation Clinical trials being pursued
=== Pharmacokinetics === Abrocitinib is quickly absorbed from the gut and generally reaches highest blood plasma concentrations within one hour. Only 1.0 to 4.4% of the dose are found unmetabolized in the urine. The half-life of abrocitinib is 5 hours and the absorption is not affected by food. A higher dose (400–800 mg) would delay the absorption to 1.5–4 hours. A steady plasma concentration of abrocitinib can be obtained within 48 hours of treatments. The dose is one daily, and abrocitinib is metabolized mainly by cytochrome P450 (CYP450) in liver such as CYP2C9, CYP2C19, CYP3A4 and CYP2B6. The major metabolites of abrocitinib are pyrrolidinone pyrimidine (inactive), 2-hydroxypropyl (active), and 3-hydroxypropyl (active). Dose reduction to half is advisable when abrocitinib is taken with strong inhibitors of CYP2C19. According to phase 1 clinical trials on abrocitinib oral dose of 200 mg, hepatic functions were not altered. However, it is advisable to reduce the dose by half in case of reduced renal function. In serious hepatic impairment and final stages of renal disease, Abrocitinib is contraindicated. Some changes may occur during the abrocitinib treatment such as the reduction in platelet counts after 4 weeks of starting Abrocitinib. However, they will return to normal at the end of the treatment. An increase in LDL, HDL, and total cholesterol levels was also recorded after 4 weeks of Abrocitinib treatment. The increased levels depend on the abrocitinib dose (15% increase in LDL with 200 mg dose versus 10% increase with 100 mg).
Chain Home, or CH for short, was the codename for the ring of coastal early warning radar stations built by the Royal Air Force (RAF) before and during the Second World War to detect and track aircraft. Initially known as RDF, and given the official name Air Ministry Experimental Station Type 1 (AMES Type 1) in 1940, the radar units were also known as Chain Home for most of their life. Chain Home was the first early warning radar network in the world and the first military radar system to reach operational status. Its effect on the war made it one of the most powerful systems of what became known as the "Wizard War". In late 1934, the Tizard Committee asked radio expert Robert Watson-Watt to comment on the repeated claims of radio death rays and reports suggesting Germany had built some sort of radio weapon. His assistant, Arnold Wilkins, demonstrated that a death ray was impossible but suggested radio could be used for long-range detection. In February 1935, a successful demonstration was arranged by placing a receiver near a BBC short wave transmitter and flying an aircraft around the area. Using commercial short wave radio hardware, Watt's team built a prototype pulsed transmitter and, by June 1935, it detected an aircraft that happened to be flying past. Basic development was completed by the end of the year, with detection ranges on the order of 100 mi (160 km). In 1936, attention was focused on a production version, and early 1937 saw the addition of height finding.
Sources: en.wikipedia.org
FVIII concentrated from donated blood plasma, or recombinant FVIII can be given to hemophiliacs to restore hemostasis. Bypassing agents such as recombinant FVIIa can be used in acquired hemophilia. Antibody formation to factor VIII can also be a major concern for patients receiving therapy against bleeding; the incidence of these inhibitors is dependent of various factors, including the factor VIII product itself.
== Waste water produced by resin regeneration == Most ion-exchange systems use columns of ion-exchange resin that are operated on a cyclic basis. During the filtration process, water flows through the resin column until the resin is considered exhausted. That happens only when water leaving the column contains more than the maximal desired concentration of the ions being removed. Resin is then regenerated by sequentially backwashing the resin bed to remove accumulated suspended solids, flushing removed ions from the resin with a concentrated solution of replacement ions, and rinsing the flushing solution from the resin. Production of backwash, flushing, and rinsing wastewater during regeneration of ion-exchange media limits the usefulness of ion exchange for wastewater treatment. Water softeners are usually regenerated with brine containing 10% sodium chloride. Aside from the soluble chloride salts of divalent cations removed from the softened water, softener regeneration wastewater contains the unused 50–70% of the sodium chloride regeneration flushing brine required to reverse ion-exchange resin equilibria. Deionizing resin regeneration with sulfuric acid and sodium hydroxide is approximately 20–40% efficient. Neutralized deionizer regeneration wastewater contains all of the removed ions plus 2.5–5 times their equivalent concentration as sodium sulfate.
For services to Child Road Safety. Kenneth Fitzpatrick. Lifeboat Operations Manager, Porthdinllaen Lifeboat Station, Royal National Lifeboat Institution. For services to Maritime Safety. Barry Flack. For services to the Jewish Community in the London Borough of Barnet. Margaret Elizabeth Flanagan. Member, Inner Wheel Club of Ballymena. For voluntary services to the community in Ballymena, County Antrim. John Campbell Forrester. President and Poppy Appeal Organiser, Driffield Branch, Royal British Legion. For voluntary service to Veterans in East Yorkshire. Claire Forsythe. Duke of Edinburgh's Award Officer, Probation Board for Northern Ireland. For services to the Rehabilitation of Offenders. Susan Joan Foster. For voluntary service in Hampshire. Richard Charles Fowler. Library Lead, Harbury Community Library, Warwickshire. For services to Libraries. Dr Jennifer Ann Frow. Volunteer, Bewdley Tennis Club. For services to Lawn Tennis in Worcestershire. Robert Francis Fyfe. Chair and Director, Runway Theatre Company. For services to the Arts and to the community in Glasgow. Melanie Jane Gardner. Fine and Decorative Arts Curator, Tullie House Museum, Carlisle. For services to Arts and Culture in Cumbria. Joseph William Garvey. For services to the community in County Armagh. Peter William Garwood. For services to the community in Barrow-in-Furness, Cumbria. Christine Frances Gatfield. Founder, Dove Cottage Day Hospice. For services to the Terminally Ill. Patricia Mary Gaywood. Membership Secretary, The Forty Club. For voluntary service to Cricket. Andrew Gell.
In 1994, National Health Laboratories acquired Allied Clinical Laboratories. The acquisition price was reduced to $204 million after federal officials issued subpoenas in an investigation of Medicare billing practices. In April 1995, Hoffmann-La Roche, a division of Roche, contributed Roche Biomedical Laboratories, Inc. and US$186.7 million in cash to National Health Laboratories Holdings, in exchange for 49.9% of the combined company. Perelman received about US$100 million from the deal, which made the new company the largest blood-testing company in the United States. The company changed its name to Laboratory Corporation of America Holdings and relocated its headquarters to Burlington, North Carolina. In July 1998, Labcorp acquired the Michigan-based laboratory division of Universal Standard Healthcare (UHCI) and made an equity investment in the company. Labcorp also became UHCI's clinical laboratory long-term testing provider but terminated this agreement in March 1999.
Sources: en.wikipedia.org
=== Withdrawal === Abrupt or rapid discontinuation of mianserin may provoke a withdrawal, the effects of which may include depression, anxiety, panic attacks, decreased appetite or anorexia, insomnia, diarrhea, nausea and vomiting, and flu-like symptoms, such as allergies or pruritus, among others.
It is an attractive target for combinatorial biosynthesis for many reasons: second generation derivatives are currently in the clinic for development; Streptomyces roseosporus, the producer organism of daptomycin, is amenable to genetic manipulation; the daptomycin biosynthetic gene cluster has been cloned, sequenced, and expressed in S. lividans; the lipopeptide biosynthetic machinery has the potential to be interrupted by variations of natural precursors, as well as precursor-directed biosynthesis, gene deletion, genetic exchange, and module exchange; the molecular engineering tools have been developed to facilitate the expression of the three individual NRPS genes from three different sites in the chromosome, using ermEp* for expression of two genes from ectopic loci; other lipopeptide gene clusters, both related and unrelated to daptomycin, have been cloned and sequenced, thus providing genes and modules to allow the generation of hybrid molecules; derivatives can be afforded via chemoenzymatic synthesis; and lastly, efforts in medicinal chemistry are able to further modify these products of molecular engineering. New derivatives of daptomycin (Figure 9) were originally generated by exchanging the third NRPS subunit (dptD) with the terminal subunits from the A54145 (Factor B1) or calcium-dependent antibiotic pathways to create molecules containing Trp13, Ile13, or Val13. dptD is responsible for incorporating the penultimate amino acid, 3-methyl-glutamic acid (3mGlu12), and the last amino acid, Kyn13, into the chain.
=== Hot air drying in drying chamber === Compact flowers like marigolds, chrysanthemums, cornflowers and zinnias dry well in a fan-assisted, convection chamber. Non-ventilated chambers are not appropriate, because they generate too much moisture. The material must be dried at a low temperature (30-35˚Celsius), over many hours. The flowers are slotted through holes in a wire mesh rack leaving room for the stems to dangle below. The time required depends upon the density of the flowers.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.